TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04201678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CLIA Group (conventional local anesthesia infiltration)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EPIAA Group (Extrapedicular infiltration anesthesia)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally
Study: NCT03023852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
Study: NCT04201678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Group (Erector Spina Block)
Description: The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered.
Study: NCT03023852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
Study: NCT05866341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nitrate-rich lettuce juice
Description: Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nitrate-depleted lettuce juice
Description: Daily consumption of 300 ml of a nitrate-depleted lettuce juice
Study: NCT00096109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04300322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pessary
Description: Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
Study: NCT00679549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy
Description: CPAP therapy is provided as an inpatient.
Study: NCT04146285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4406F
Description: Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion.
Study: NCT04652011

Intervention type: PROCEDURE
Intervention: Minimally Invasive Gynecologic Surgery
Description: Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)

Intervention type: PROCEDURE
Intervention: osteopathic manipulative treatment
Description: Osteopathic manipulative treatment

Intervention type: DRUG
Intervention: Pain killer
Description: Common pain killer (paracetamol, Ibuprofen, ketoprofen)
Study: NCT01801462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Study: NCT00646711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote Delayed-Release/Depakote Sprinkle
Description: Administered according to the subject's usual regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote ER
Description: Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
Study: NCT04054453

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intra-partum care bundle invoking 4 elements
Description: Care bundle involving all the 4 elements
Study: NCT02161198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Y-75
Description: Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
Study: NCT04255121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% adrenaline lidocaine associated with 4.2% sodium bicarbonate
Description: conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% adrenaline lidocaine
Description: conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
Study: NCT03713697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pap testing
Description: Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collection for HPV testing
Description: Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
Study: NCT04035577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile self-help intervention
Description: During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
Study: NCT03382288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYESTAR 900
Description: EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
Study: NCT03153098

Intervention type: BEHAVIORAL
Intervention: Active Herts
Description: Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.

Intervention type: BEHAVIORAL
Intervention: Active Herts
Description: Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
Study: NCT00264498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection
Study: NCT02600598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Gel, 0.037%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Gel, 0.037%
Study: NCT04116281

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation after breast cancer surgery
Description: All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation after breast cancer surgery
Description: All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
Study: NCT02148653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Description: A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: A nutritionally well formulated diet that excludes the functional food items present in the MFD.
Study: NCT00506272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring and insulin administration
Description: Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
Study: NCT02972814

Intervention type: DEVICE
Intervention: Laboratory based troponin test
Description: acquisition of blood troponin level by Roche Cobas E 603

Intervention type: DEVICE
Intervention: Point of care based troponin test 1
Description: acquisition of blood troponin level by Radiometer EQT 90 Flex
Study: NCT04604964

Intervention type: OTHER
Intervention: Evaluation of anastomotic leakage occurrence
Description: Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
Study: NCT02622490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two test meals with two different macronutrient compositions
Description: Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
Study: NCT02972814

Intervention type: DEVICE
Intervention: Point of care based troponin test 2
Description: acquisition of blood troponin level by Philips Minicare I-20
Study: NCT01041768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
Study: NCT03591627

Intervention type: DIAGNOSTIC_TEST
Intervention: Transesophageal echocardiography
Description: Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
Study: NCT02019238

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Vein Isolation procedure
Description: comparing the efficacy of PVI ablation vs PVI combined with empiric ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation procedure
Description: comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
Study: NCT00740870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Pulmonary Valve replacement
Description: Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
Study: NCT02370030

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline malate
Description: Active comparator: 10 g/day citrulline malate during 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Citrulline malate
Description: Active comparator: 10 g/day citrulline malate during 7 days
Study: NCT01068106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobori® (Biodegradable polymer limus-eluting stents)
Description: due randomization biodegradable polymer limus-eluting stents will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience-V® (Permanent polymer limus-eluting stent)
Description: due randomization permanent polymer limus-eluting stent will be implanted
Study: NCT03133078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step-Down Test (2 min)
Description: The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side hop test (30 s)
Description: The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
Study: NCT00537329

Intervention type: DRUG
Group type: OTHER
Intervention: Anidulafungin
Description: Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
Study: NCT04082377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver with tidal volume (RM TV)
Description: The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver by PEEP (RM PEEP)
Description: The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
Study: NCT00953212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Description: metoprolol 25mg by mouth every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Description: metoprolol 25mg by mouth every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Description: metoprolol 25mg by mouth every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Description: metoprolol 25mg by mouth every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascorbic acid
Description: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascorbic acid
Description: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
Study: NCT00948610

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remicade
Description: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
Study: NCT01299298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
Study: NCT04620369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Instill isotonic nasal saline intranasally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Geranium in Sesame Oil Nasal Spray
Description: Instill intranasally
Study: NCT01657643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03900026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.